<DOC>
	<DOC>NCT00212667</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.</brief_summary>
	<brief_title>Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1. Patients with fragility fracture according to the diagnostic criterial for the diagnosis of Primary Osteoporosis 2. Patients having radiographically confirmed vertebral (T4L4) fractures 3. Other inclusion criteria as specified in the study protocol 1. Patients having secondary osteoporosis or another condition that presents low bone mass 2. Patients having findings on Xray that affect evaluation of vertebral fracture 3. Patients that have been administered bisphosphonate derivatives 4. Other exclusion criteria as specified in the study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>ONO-5920, osteoporosis, bisphosphonate</keyword>
</DOC>